Published in Cancer Weekly, June 26th, 2001
The researchers, who work at the University of Texas M.D. Anderson Cancer Center, report elevated levels of the inducible enzyme cyclooxygenase (COX)-2 are common in aggressive forms of glioma, and patients with tumors that express higher levels of the enzyme encounter poorer survival rates.
"We examined COX-2 expression by immunohistochemistry in tumor specimens from 66 patients with low- and high-grade astrocytomas and correlated the percentage of COX-2 expression with patient survival," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.